Accessibility helpSkip to navigationSkip to contentSkip to footer
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Israel-Hamas war
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    Most Read
    • Donald Trump scores big win in South Carolina Republican primary
    • Global house prices rebound as economists predict turning point
    • Trump says he is a ‘dissident’ under siege from thugs in bleak speech
    • Malaysia’s prime minister decries ‘China-phobia’ among US and western allies
    • Trump pivots to race against Biden after crushing Haley in South Carolina
  • UK
    Sections
    • UK Home
    • UK Economy
    • UK Politics
    • UK Companies
    • Personal Finance
    Most Read
    • UK Conservatives battle to retain ‘true blue’ rural heartlands
    • Conservative party suspends Lee Anderson over Sadiq Khan comments
    • UK deputy PM declines to say if Lee Anderson comments over Sadiq Khan were racist
    • Birth rate drops to new low in England and Wales
    • ‘Macho’ all-male Rochdale by-election fuels political divisions over Gaza
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Jim Ratcliffe warns EU bureaucracy will drive away industry’s investments
    • Warren Buffett admits Berkshire Hathaway’s days of ‘eye-popping’ gains are over
    • Indonesia to wipe out global nickel rivals, warns French miner Eramet chief
    • Goldman insider-trading conviction shows UK watchdog sharpening its teeth
    • European football needs innovation and drama, says Real Madrid and FC Barcelona investor
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Cryptofinance
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Wealth Management
    • Moral Money
    • ETF Hub
    • Fund Management
    • Trading
    Most Read
    • Indonesia to wipe out global nickel rivals, warns French miner Eramet chief
    • How Germany’s steelmakers plan to go green
    • Goldman insider-trading conviction shows UK watchdog sharpening its teeth
    • $100mn in crypto payments traced to Myanmar-based ‘scammers’
    • Public service pensions are the elephant in the room
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
    Most Read
    • Why is Nikki Haley still running?
    • Western timidity has only emboldened Putin
    • The global trade system is in desperate need of an overhaul
    • The forgotten war
    • The metropolitan elite has ignored farmers for too long
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    • Working It
    Most Read
    • Fewer trips, fewer planes: business travellers rethink old habits
    • The menace of the overblown job title
    • ‘Every person slips at some point’: how businesses are managing the four-day week
    • ‘The one thing I’ve always had is deal flow’: RedBird’s Gerry Cardinale
    • Good news. We’ve got the contract for the worst idea in the world
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • Zone of Interest director Jonathan Glazer: ‘I’m suspicious of people making Holocaust films’
    • Six cool California hotels to book now
    • Across ‘Saxon Switzerland’ in the footsteps of Caspar David Friedrich
    • Can a friendship app cure loneliness?
    • ‘They are among us’: Russia’s terrifyingly effective poisoning operation
  • HTSI
MenuSearch
  • Home
  • World
  • UK
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Work & Careers
  • Life & Arts
  • HTSI
Financial Times
SubscribeSign In

Coronavirus treatment

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Wednesday, 21 February, 2024
    Coronavirus
    Anti-viral protein found to be important long Covid indicator

    Discovery boosts efforts to develop ‘biomarkers’ for debilitating condition and enable treatments

    A worker holds a blood sample in a test tube
  • Thursday, 15 February, 2024
    News in-depth
    Scientists grapple with long Covid puzzle as millions fall sick

    Fears condition’s range of symptoms and link to chronic diseases will have lasting impact on health systems

    Montage of virus and X-ray view of upper human body
  • Tuesday, 6 February, 2024
    LexPharmaceuticals sector
    Big Pharma still needs trial success to overcome looming patent panic Premium content

    Pharma companies, while talking up pipelines, are turning to deals to boost their growth outlook

    A Bristol Myers Squibb sign on a facility in Cambridge, Massachusetts, US
  • Sunday, 28 January, 2024
    The FT ViewThe editorial board
    The worrying return of a nasty virus

    Better awareness and access are needed to rebuild measles vaccination rates

    A toddler in her mothers arms while she is inoculated in the arm
  • Thursday, 4 January, 2024
    Raymond Duch
    It’s time to start using cash incentives to boost vaccine take-up

    A trial of $3 payments for getting a Covid jab in rural Ghana offers a game-changing way to meet public health goals

    A nurse wearing a facemask vaccinates a man in a Ghana hospital
  • Monday, 1 January, 2024
    Expired Pfizer Covid antiviral drugs set to cost Europe $2.2bn, data shows

    Millions of Paxlovid pills have gone unused as tight controls restrict access

    Pfizer’s drug Paxlovid undergoes testing
  • Sunday, 24 December, 2023
    Coronavirus
    New Covid variant gains ground in US ahead of holiday season

    Americans’ interest in vaccinations has flagged despite efforts to boost uptake of latest jab

    A shopper wearing a mask and carrying bags in San Francisco
  • Wednesday, 13 December, 2023
    LexPfizer Inc
    Pfizer: pharma group needs weight loss drug to secure post-Covid future Premium content

    Company would have been better off following Roche’s route to market for anti-obesity treatment

    A vial and syringe in front of a Pfizer logo
  • Wednesday, 22 November, 2023
    AstraZeneca PLC
    AstraZeneca fights accusations its Covid-19 jab was ‘defective’

    Vaccine recipient claims he suffered side effect of severe blood clot

    A health worker prepares a dose of the AstraZeneca Covid-19 vaccine
  • Wednesday, 15 November, 2023
    FT SeriesTech Champions
    Airfinity gives decision makers big picture on health

    Covid may have abated, but emerging diseases and new drug categories are keeping the analytics firm busy

    Portrait of Airfinity founder Rasmus Bech Hansen
  • Monday, 6 November, 2023
    BioNTech
    BioNTech cuts revenue forecast on lower demand for Covid jabs

    German group slashes guidance by €1bn and reduces spending as it expects fewer first vaccine doses and lower boosting

    A patient receiving a vaccine dose
  • Thursday, 2 November, 2023
    Moderna
    Moderna shares hit by quarterly loss and waning Covid vaccine demand

    Biotech blames weaker US sales after lowering full-year forecast

    Syringes with needles in front of Moderna’s logo
  • Tuesday, 17 October, 2023
    Disease control and prevention
    Global warning system essential to beat future pandemics, says Cepi chief

    Call for rapid detection comes as pharma groups criticise draft WHO treaty on how to avoid another health crisis

    Richard Hatchett
  • Monday, 16 October, 2023
    BioNTech
    BioNTech writes down €900mn on Covid-19 vaccines

    Biotech group hit by lower demand, with majority of write-offs relating to raw materials bought during pandemic

    A dose of the BioNtech/Pfizer Covid vaccine is administered to a person at a vaccination centre
  • Sunday, 15 October, 2023
    Covid-19 vaccines
    EU delays approval of Novavax’s revised Covid jab

    US biotech has been struggling to overcome fall in demand for coronavirus jabs

  • Monday, 9 October, 2023
    Covid antivirals lose spark as regulatory scrutiny increases

    Doubts grow over safety and effectiveness of drugs that were marketed as coronavirus treatments

    A person dressed in a white clinical coat holds a box of the pills up in front of a larger cardboard box containing dozens more samples
  • Wednesday, 4 October, 2023
    Covid-19 vaccines
    Moderna reports trial success for dual Covid and flu vaccine

    Combined jab as effective as separate shots in early stage tests

    The Moderna Covid-19 vaccine is loaded into a syringe
  • Tuesday, 3 October, 2023
    News in-depthPfizer Inc
    Covid vaccine winners suffer reversal of fortune

    Companies have yet to provide investors with convincing post-pandemic strategies

    A montage of a nurse preparing a Covid-19 Pfizer vaccine, and the BioNTech and Moderna logos
  • Monday, 2 October, 2023
    Disease control and prevention
    WHO approves second malaria jab for children

    Oxford university shot expected to deliver ‘sufficient’ supply for all at-risk infants

    A child sits under a mosquito net
  • Monday, 2 October, 2023
    Nobel prizes
    Scientists whose work led to Covid mRNA vaccines win Nobel Prize

    Katalin Karikó and Drew Weissman praised for role in ‘unprecedented rate of development’ of coronavirus jabs

    Katalin Karikó and Drew Weissman
  • Tuesday, 26 September, 2023
    Covid-19 vaccines
    EU in talks with Moderna over new vaccine supply deal

    Brussels launches talks for mRNA jabs to augment existing contract with BioNTech/Pfizer

    A pharmacist administers a Covid jab made by Moderna
  • Monday, 25 September, 2023
    Covid antiviral drug linked to ‘transmissible’ mutations, research finds

    Big-selling molnupiravir treatment produces permanent mutations that can be passed from patient to patient

    An experimental COVID-19 treatment pill, called molnupiravir
  • Thursday, 14 September, 2023
    Special Report
    FT Health: Communicable Diseases

    Climate change helps the spread of infectious diseases. Plus: rise in fungal infections highlights risks of antimicrobial resistance; Sydney shows how to almost eliminate HIV transmission; wait goes on for effective Long Covid treatments

    a tiger mosquito on a person’s skin
  • Wednesday, 13 September, 2023
    Anjana Ahuja
    The rush to outpace Covid variants

    At least three descendants of Omicron have scientists on alert and vaccination programmes speeding up

    Andy Carter illustration of a man running away from coronavirus proteins while pushing a shopping trolley with a vaccine syringe in it
  • Monday, 11 September, 2023
    Covid-19 vaccines
    FDA approves new Covid-19 boosters from Pfizer and Moderna

    Drug regulator’s decision is the first step towards a new round of jabs as cases rise in the US

    A nurse fills a syringe with Covid-19 vaccine
Previous page You are on page 1 Next page

Recommended

Covid-19 vaccines
Covid-19 vaccine tracker: Lowest-income countries lag further behind rest of the world
Covid-19 vaccines
Covid vaccine development: The shots available and the doses administered
Covid-19 vaccines
In graphics: the UK vaccine supply chain
Coronavirus: free to read
Coronavirus tracker: the latest figures as countries fight the Covid-19 resurgence
Coronavirus tracker

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookie PolicyManage CookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsProfessional SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on XFT ChannelsFT Schools

Tools

PortfolioFT AppFT Digital EditionFT EditAlerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

Community & Events

FT CommunityFT Live EventsFT ForumsFT Board NetworkBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2024. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

UK Edition

Subscribe for full access
  • Switch to International Edition

Top sections

  • Home
  • World
    • Israel-Hamas war
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
  • UK
    • UK Economy
    • UK Politics
    • UK Companies
    • Personal Finance
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
    • Artificial intelligence
    • Semiconductors
    • Cyber Security
    • Social Media
  • Markets
    • Alphaville
    • Markets Data
    • Cryptofinance
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Wealth Management
    • Moral Money
    • ETF Hub
    • Fund Management
    • Trading
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    • Working It
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • HTSI
  • Special Reports

FT recommends

  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • Visual and data journalism
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Live Events
  • FT Forums
  • Board Director Programme
  • myFT
  • Portfolio
  • FT Digital Edition
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In